ATX Share Price Performance
AU$0.11
0.04 (52.78%)
Price AU$0.11
Share Pricen/a
Amplia Therapeutics Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
ATX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Amplia Therapeutics Limited Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.015
- 94.06%
- -158.46%
- 0%
About ATX
- Founded
- 2000
- Employees
- n/a
- CEO
- WebsiteView website
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
